The Phase 1 study will evaluate the safety, tolerability, pharmacokinetic profile and antiviral activity of ACH-2684.
The trial aims to enroll around 78 healthy subjects and 40 HCV infected patients.
In preclinical studies, ACH-2684 showed pico-molar potency, prominent pharmacokinetic properties and safety profile at high drug exposures.
Achillion president and CEO Michael Kishbauch said they expect to shortly launch the 12-week segment of the Phase 2 trial of their lead ACH-1625 protease inhibitor, as well as a Phase 1 trial of ACH-2928 NS5A inhibitor.
"We believe we remain poised to deliver a trio of important HCV clinical milestones near the end of this year, namely, 12-week EVR results on ACH-1625 and human proof-of-concept data on both ACH-2684 and ACH-2928," Kishbauch said.